191 related articles for article (PubMed ID: 31604755)
1. Opioid agonist therapy during residential treatment of opioid use disorder: Cohort study on access and outcomes.
Spithoff S; Meaney C; Urbanoski K; Harrington K; Que B; Kahan M; Leece P; Shehadeh V; Sullivan F
Can Fam Physician; 2019 Oct; 65(10):e443-e452. PubMed ID: 31604755
[TBL] [Abstract][Full Text] [Related]
2. High-intensity cannabis use is associated with retention in opioid agonist treatment: a longitudinal analysis.
Socías ME; Wood E; Lake S; Nolan S; Fairbairn N; Hayashi K; Shulha HP; Liu S; Kerr T; Milloy MJ
Addiction; 2018 Dec; 113(12):2250-2258. PubMed ID: 30238568
[TBL] [Abstract][Full Text] [Related]
3. Quality of primary care among individuals receiving treatment for opioid use disorder.
Spithoff S; Kiran T; Khuu W; Kahan M; Guan Q; Tadrous M; Leece P; Martins D; Gomes T
Can Fam Physician; 2019 May; 65(5):343-351. PubMed ID: 31088874
[TBL] [Abstract][Full Text] [Related]
4. The effect of entry and retention in opioid agonist treatment on contact with the criminal justice system among opioid-dependent people: a retrospective cohort study.
Gisev N; Bharat C; Larney S; Dobbins T; Weatherburn D; Hickman M; Farrell M; Degenhardt L
Lancet Public Health; 2019 Jul; 4(7):e334-e342. PubMed ID: 31201133
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Publicly Funded Treatment of Opioid Use Disorder in California.
Krebs E; Enns B; Evans E; Urada D; Anglin MD; Rawson RA; Hser YI; Nosyk B
Ann Intern Med; 2018 Jan; 168(1):10-19. PubMed ID: 29159398
[TBL] [Abstract][Full Text] [Related]
6. The effectiveness of telemedicine-delivered opioid agonist therapy in a supervised clinical setting.
Eibl JK; Gauthier G; Pellegrini D; Daiter J; Varenbut M; Hogenbirk JC; Marsh DC
Drug Alcohol Depend; 2017 Jul; 176():133-138. PubMed ID: 28535455
[TBL] [Abstract][Full Text] [Related]
7. Differences in Availability and Use of Medications for Opioid Use Disorder in Residential Treatment Settings in the United States.
Huhn AS; Hobelmann JG; Strickland JC; Oyler GA; Bergeria CL; Umbricht A; Dunn KE
JAMA Netw Open; 2020 Feb; 3(2):e1920843. PubMed ID: 32031650
[TBL] [Abstract][Full Text] [Related]
8. Opioid agonist treatment (OAT) experiences and release plans among federally incarcerated individuals with opioid use disorder (OUD) in Ontario, Canada: a mixed-methods study.
Russell C; Nafeh F; Pang M; MacDonald SF; Derkzen D; Rehm J; Fischer B
BMC Public Health; 2022 Mar; 22(1):436. PubMed ID: 35246083
[TBL] [Abstract][Full Text] [Related]
9. Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation.
Gomes T; Campbell TJ; Kitchen SA; Garg R; Bozinoff N; Men S; Tadrous M; Munro C; Antoniou T; Werb D; Wyman J
JAMA; 2022 Mar; 327(9):846-855. PubMed ID: 35230394
[TBL] [Abstract][Full Text] [Related]
10. The cascade of care for opioid use disorder: a retrospective study in British Columbia, Canada.
Piske M; Zhou H; Min JE; Hongdilokkul N; Pearce LA; Homayra F; Socias ME; McGowan G; Nosyk B
Addiction; 2020 Aug; 115(8):1482-1493. PubMed ID: 31899565
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the gap in delivery of opioid agonist therapy among individuals with opioid-related health problems: a population-based retrospective cohort study.
Paul LA; Bayoumi AM; Chen C; Kocovska E; Smith BT; Raboud JM; Gomes T; Kendall C; Rosella LC; Bitonti-Bengert L; Rush B; Yu M; Spithoff S; Crichlow F; Wright A; Watford J; Besharah J; Munro C; Taha S; Nosyk B; Strike C; Manson H; Kahan M; Leece P
Addiction; 2023 Apr; 118(4):686-697. PubMed ID: 36401610
[TBL] [Abstract][Full Text] [Related]
12. Reductions in emergency department presentations associated with opioid agonist treatment vary by geographic location: A retrospective study in New South Wales, Australia.
Jones NR; Shanahan M; Dobbins T; Degenhardt L; Montebello M; Gisev N; Larney S
Drug Alcohol Rev; 2019 Sep; 38(6):690-698. PubMed ID: 31577058
[TBL] [Abstract][Full Text] [Related]
13. A cohort study evaluating the association between concurrent mental disorders, mortality, morbidity, and continuous treatment retention for patients in opioid agonist treatment (OAT) across Ontario, Canada, using administrative health data.
Morin KA; Eibl JK; Gauthier G; Rush B; Mushquash C; Lightfoot NE; Marsh DC
Harm Reduct J; 2020 Jul; 17(1):51. PubMed ID: 32703310
[TBL] [Abstract][Full Text] [Related]
14. Does opioid agonist treatment reduce overdose mortality risk in people who are older or have physical comorbidities? Cohort study using linked administrative health data in New South Wales, Australia, 2002-17.
Larney S; Jones NR; Hickman M; Nielsen S; Ali R; Degenhardt L
Addiction; 2023 Aug; 118(8):1527-1539. PubMed ID: 36843415
[TBL] [Abstract][Full Text] [Related]
15. Barriers to accessing treatment for pregnant women with opioid use disorder in Appalachian states.
Patrick SW; Buntin MB; Martin PR; Scott TA; Dupont W; Richards M; Cooper WO
Subst Abus; 2019; 40(3):356-362. PubMed ID: 29949454
[No Abstract] [Full Text] [Related]
16. Utilization of buprenorphine and methadone among opioid users who inject drugs.
Tsui JI; Burt R; Thiede H; Glick SN
Subst Abus; 2018 Jan; 39(1):83-88. PubMed ID: 28796591
[TBL] [Abstract][Full Text] [Related]
17. Inability to contact opioid agonist therapy prescribers during the COVID-19 pandemic in a Canadian setting: a cross-sectional analysis among people on opioid agonist therapy.
Moallef S; DeBeck K; Fairbairn N; Cui Z; Brar R; Wilson D; Johnson C; Milloy MJ; Hayashi K
Addict Sci Clin Pract; 2022 Dec; 17(1):73. PubMed ID: 36522789
[TBL] [Abstract][Full Text] [Related]
18. The Association Between Self-Reported Anxiety and Retention in Opioid Agonist Therapy: Findings From a Canadian Pragmatic Trial.
Bahji A; Bastien G; Bach P; Choi J; Le Foll B; Lim R; Jutras-Aswad D; Socias ME
Can J Psychiatry; 2024 Mar; 69(3):172-182. PubMed ID: 37697811
[TBL] [Abstract][Full Text] [Related]
19. Assessing the determinants of completing OAT induction and long-term retention: A population-based study in British Columbia, Canada.
Kurz M; Min JE; Dale LM; Nosyk B
J Subst Abuse Treat; 2022 Feb; 133():108647. PubMed ID: 34740484
[TBL] [Abstract][Full Text] [Related]
20. Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population-based propensity-score matched cohort study.
Gomes T; McCormack D; Bozinoff N; Tadrous M; Antoniou T; Munro C; Campbell T; Paterson JM; Mamdani M; Sproule B
Addiction; 2022 Jul; 117(7):1972-1981. PubMed ID: 35257434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
